Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6331 to 6345 of 8979 results

  1. Changes to NICE's cost-effectiveness thresholds confirmed

    The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

  2. New life-extending treatment given the green light for people with rare form of bile duct cancer

    A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

  3. Have your say on NICE's adoption of the new EQ-5D-5L value set

    We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.

  4. 500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

    A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

  5. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  6. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

  7. International collaboration provides new guidance on the use of surrogate endpoints in cost-effectiveness analysis

    Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients

  8. Patients to get new medicines up to 6 months sooner

    A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) will help bring medicines to patients faster.

  9. Improving outcomes in haemato-oncology cancer (CSG3)

    This guidance has been updated and replaced by NICE guideline NG47.

  10. Improving outcomes in colorectal cancer (CSG5)

    This guidance has been updated and replaced by NICE guideline NG151.

  11. Transanal total mesorectal excision of the rectum (IPG514)

    This guidance has been updated and replaced by NICE HealthTech guidance 603.

  12. Irreversible electroporation for treating prostate cancer (IPG768)

    We have moved interventional procedures guidance 768 to become HealthTech guidance 688. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (IPG805)

    We have moved interventional procedures guidance 805 to become HealthTech guidance 752. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's (IPG796)

    We have moved interventional procedures guidance 796 to become HealthTech guidance 733. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  15. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (IPG797)

    We have moved interventional procedures guidance 797 to become HealthTech guidance 734. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.